Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Burcon NutraScienceAptose BiosciencesSensei BiotherapeuticsDecibel TherapeuticsNexImmune
SymbolTSE:BUTSE:APSNASDAQ:SNSENASDAQ:DBTXNASDAQ:NEXI
Price Information
Current PriceC$5.04C$6.08$12.74$9.71$18.47
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.32.02.22.0
Analysis Score1.53.53.54.53.5
Community Score2.62.85.05.05.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.71.7
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price TargetC$5.00C$12.00$29.50$28.80$33.33
% Upside from Price Target-0.79% downside97.37% upside131.55% upside196.60% upside80.47% upside
Trade Information
Market CapC$543.00 millionC$566.20 million$403.76 million$245.04 million$417.84 million
BetaN/AN/AN/AN/AN/A
Average Volume553,47161,527219,687174,151135,191
Sales & Book Value
Annual RevenueC$12,045.00N/AN/AN/AN/A
Price / Sales44,814.37N/AN/AN/AN/A
CashflowC$0.11 per shareC$1.31 per shareN/AN/AN/A
Price / Cash45.984.66N/AN/AN/A
Book ValueC$0.33 per shareC$1.34 per shareN/AN/AN/A
Price / Book15.46N/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC$0.00C($0.84)N/AN/AN/A
Trailing P/E Ratio5,040.00N/A0.000.000.00
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%0.90%N/AN/AN/A
Current Ratio12.61%18.36%N/AN/AN/A
Quick Ratio12.21%17.97%N/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees2131N/A40N/A
Shares Outstanding107.10 million88.89 million30.59 million24.90 million22.76 million
Next Earnings Date7/5/2021 (Estimated)5/4/2021 (Estimated)6/24/2021 (Estimated)7/5/2021 (Estimated)6/30/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
NexImmune (NASDAQ:NEXI) Shares Gap Up to $23.89NexImmune (NASDAQ:NEXI) Shares Gap Up to $23.89
americanbankingnews.com - April 15 at 10:52 AM
Raymond James Predicts Over 60% Rally for These 2 StocksRaymond James Predicts Over 60% Rally for These 2 Stocks
finance.yahoo.com - April 13 at 2:11 PM
NexImmune Reports Fiscal Year 2020 Financial Results and Recent UpdatesNexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
finance.yahoo.com - March 31 at 8:18 PM
NexImmune (NASDAQ:NEXI) Earns Outperform Rating from Analysts at Raymond JamesNexImmune (NASDAQ:NEXI) Earns Outperform Rating from Analysts at Raymond James
americanbankingnews.com - March 31 at 5:27 PM
Md. biotech plans aggressive hiring, growth with IPO proceeds in handMd. biotech plans aggressive hiring, growth with IPO proceeds in hand
bizjournals.com - March 23 at 9:12 AM
5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week
247wallst.com - March 12 at 10:20 PM
NexImmune Inc Registered Shs OverweightNexImmune Inc Registered Shs Overweight
markets.businessinsider.com - March 11 at 2:16 PM
Analyzing The Price Action In NexImmune Stock TodayAnalyzing The Price Action In NexImmune Stock Today
msn.com - March 9 at 1:45 PM
NexImmune to Present at the 2021 Barclays Global Healthcare ConferenceNexImmune to Present at the 2021 Barclays Global Healthcare Conference
finance.yahoo.com - March 2 at 6:45 PM
Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc.
finance.yahoo.com - February 24 at 10:09 AM
Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmuneBarer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune
finance.yahoo.com - February 23 at 8:14 AM
Gaithersburg’s NexImmune secures $126.5M from IPO. Here’s its plan for the proceeds.Gaithersburg’s NexImmune secures $126.5M from IPO. Here’s its plan for the proceeds.
bizjournals.com - February 19 at 1:42 PM
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of ...NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of ...
apnews.com - February 17 at 11:03 PM
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 17 at 11:03 PM
DateCompanyBrokerageAction
2/18/2021Burcon NutraScienceCanaccord GenuityBoost Price Target
8/31/2020Burcon NutraScienceEight CapitalBoost Price Target
8/28/2020Burcon NutraScienceBeacon SecuritiesReiterated Rating
10/19/2020Aptose BiosciencesCantor FitzgeraldReiterated Rating
9/22/2020Aptose BiosciencesAlliance Global PartnersReiterated Rating
5/23/2019Aptose BiosciencesRoth CapitalReiterated Rating
3/1/2019Aptose BiosciencesRoyal Bank of CanadaReiterated Rating
12/3/2018Aptose BiosciencesHC WainwrightReiterated Rating
11/16/2018Aptose BiosciencesB. RileyReiterated Rating
3/8/2021Sensei BiotherapeuticsPiper SandlerInitiated Coverage
3/8/2021Sensei BiotherapeuticsOppenheimerInitiated Coverage
3/1/2021Sensei BiotherapeuticsCitigroupInitiated Coverage
3/1/2021Sensei BiotherapeuticsBerenberg BankInitiated Coverage
3/15/2021Decibel TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/15/2021Decibel TherapeuticsSVB LeerinkInitiated Coverage
3/15/2021Decibel TherapeuticsBarclaysInitiated Coverage
3/15/2021Decibel TherapeuticsBMO Capital MarketsInitiated Coverage
3/31/2021NexImmuneRaymond JamesInitiated Coverage
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.